Merck shares drop 10% as pharma giant scraps trial of promising cancer drug 25 de junho de 2024 by in News Merck & Co called off a Phase III trial of its promising cancer drug Xevinapant after an independent panel concluded it is unlikely to meet its goals Compartilhe isso:Clique para compartilhar no Twitter(abre em nova janela)Clique para compartilhar no Facebook(abre em nova janela) Relacionado 25 de junho de 2024